ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1MRK | MERCK & CO INC | Healthcare | $362.27B | 40.49% |
2GILD | GILEAD SCIENCES INC | Healthcare | $208.31B | 23.28% |
3MRNA | MODERNA INC | Healthcare | $93.61B | 10.46% |
4ZTS | ZOETIS INC | Healthcare | $33.71B | 3.77% |
5INSM | INSMED INC | Healthcare | $25.90B | 2.89% |
6VTRS | VIATRIS INC | Healthcare | $23.70B | 2.65% |
7EXEL | EXELIXIS INC | Healthcare | $17.04B | 1.90% |
8BAX | BAXTER INTERNATIONAL INC | Healthcare | $13.32B | 1.49% |
9PCVX | VAXCYTE INC | Healthcare | $10.24B | 1.14% |
10RYTM | RHYTHM PHARMACEUTICALS INC | Healthcare | $7.62B | 0.85% |
11CHE | CHEMED CORP | Healthcare | $7.16B | 0.80% |
12DOCS | DOXIMITY INC | Healthcare | $5.92B | 0.66% |
13SRRK | SCHOLAR ROCK HOLDING CORP | Healthcare | $5.27B | 0.59% |
14TVTX | TRAVERE THERAPEUTICS INC | Healthcare | $4.95B | 0.55% |
15ADPT | ADAPTIVE BIOTECHNOLOGIES CORP | Healthcare | $4.77B | 0.53% |
16IONS | IONIS PHARMACEUTICALS INC | Healthcare | $4.55B | 0.51% |
17CRSP | CRISPR THERAPEUTICS AG | Healthcare | $4.13B | 0.46% |
18TARS | TARSUS PHARMACEUTICALS INC | Healthcare | $3.79B | 0.42% |
19VKTX | VIKING THERAPEUTICS INC | Healthcare | $3.52B | 0.39% |
20ACHC | ACADIA HEALTHCARE COMPANY INC | Healthcare | $3.52B | 0.39% |
21XNCR | XENCOR INC | Healthcare | $2.86B | 0.32% |
22PGNY | PROGYNY INC | Healthcare | $2.69B | 0.30% |
23RCUS | ARCUS BIOSCIENCES INC | Healthcare | $2.56B | 0.29% |
24PRGO | PERRIGO CO PLC | Healthcare | $2.25B | 0.25% |
25VERA | VERA THERAPEUTICS INC | Healthcare | $2.10B | 0.23% |
26REPL | REPLIMUNE GROUP INC | Healthcare | $2.08B | 0.23% |
27MRVI | MARAVAI LIFESCIENCES HOLDINGS INC | Healthcare | $2.00B | 0.22% |
28AZTA | AZENTA INC | Healthcare | $1.92B | 0.21% |
29AGIO | AGIOS PHARMACEUTICALS INC | Healthcare | $1.90B | 0.21% |
30ZYME | ZYMEWORKS INC | Healthcare | $1.83B | 0.20% |
31BFLY | BUTTERFLY NETWORK INC | Healthcare | $1.78B | 0.20% |
32ENOV | ENOVIS CORP | Healthcare | $1.59B | 0.18% |
33WGS | GENEDX HOLDINGS CORP | Healthcare | $1.55B | 0.17% |
34RAPP | RAPPORT THERAPEUTICS INC | Healthcare | $1.53B | 0.17% |
35NTLA | INTELLIA THERAPEUTICS INC | Healthcare | $1.48B | 0.17% |
36USPH | U S PHYSICAL THERAPY INC | Healthcare | $1.47B | 0.16% |
37MLYS | MINERALYS THERAPEUTICS INC | Healthcare | $1.37B | 0.15% |
38PRCT | PROCEPT BIOROBOTICS CORP | Healthcare | $1.35B | 0.15% |
39DRTS | ALPHA TAU MEDICAL LTD | Healthcare | $1.23B | 0.14% |
40AHCO | ADAPTHEALTH CORP | Healthcare | $1.07B | 0.12% |
41HROW | HARROW INC | Healthcare | $1.06B | 0.12% |
42CBLL | CERIBELL INC | Healthcare | $1.02B | 0.11% |
43QDEL | QUIDELORTHO CORP | Healthcare | $729M | 0.08% |
44CTKB | CYTEK BIOSCIENCES INC | Healthcare | $722M | 0.08% |
45FLGT | FULGENT GENETICS INC | Healthcare | $694M | 0.08% |
46KURA | KURA ONCOLOGY INC | Healthcare | $683M | 0.08% |
47DNA | GINKGO BIOWORKS HOLDINGS INC | Healthcare | $663M | 0.07% |
48CGEM | CULLINAN THERAPEUTICS INC | Healthcare | $662M | 0.07% |
49SGHT | SIGHT SCIENCES INC | Healthcare | $611M | 0.07% |
50MYGN | MYRIAD GENETICS INC | Healthcare | $545M | 0.06% |
51TKNO | ALPHA TEKNOVA INC | Healthcare | $522M | 0.06% |
52DMAC | DIAMEDICA THERAPEUTICS INC | Healthcare | $503M | 0.06% |
53OBIO | ORCHESTRA BIOMED HOLDINGS INC | Healthcare | $484M | 0.05% |
54CARL | CARLSMED INC | Healthcare | $474M | 0.05% |
55ARVN | ARVINAS INC | Healthcare | $450M | 0.05% |
56SI | SHOULDER INNOVATIONS INC | Healthcare | $441M | 0.05% |
57PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $423M | 0.05% |
58TECX | TECTONIC THERAPEUTIC INC | Healthcare | $420M | 0.05% |
59NPCE | NEUROPACE INC | Healthcare | $413M | 0.05% |
60LYEL | LYELL IMMUNOPHARMA INC | Healthcare | $385M | 0.04% |
61TMCI | TREACE MEDICAL CONCEPTS INC | Healthcare | $350M | 0.04% |
62PEPG | PEPGEN INC | Healthcare | $349M | 0.04% |
63CV | CAPSOVISION INC | Healthcare | $314M | 0.04% |
64EBS | EMERGENT BIOSOLUTIONS INC | Healthcare | $303M | 0.03% |
65ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $243M | 0.03% |
66AMWL | AMERICAN WELL CORP | Healthcare | $207M | 0.02% |
67TRDA | ENTRADA THERAPEUTICS INC | Healthcare | $202M | 0.02% |
68KROS | KEROS THERAPEUTICS INC | Healthcare | $198M | 0.02% |
69KRRO | KORRO BIO INC | Healthcare | $196M | 0.02% |
70INGN | INOGEN INC | Healthcare | $146M | 0.02% |
71CUE | CUE BIOPHARMA INC | Healthcare | $127M | 0.01% |
72CPIX | CUMBERLAND PHARMACEUTICALS INC | Healthcare | $99M | 0.01% |
73JYNT | JOINT CORP | Healthcare | $92M | 0.01% |
74NTRB | NUTRIBAND INC | Healthcare | $73M | 0.01% |
75YARW | YARROW BIOSCIENCE INC | Healthcare | $52M | 0.01% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $894.79B. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 94% toward Large, 87% toward Growth. +29% unclassified (10 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 75 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
No more than 25% of total assets may be invested in the securities of any one issuer.
At least 50% of total assets must sit in cash, government securities, other RICs, and other securities limited to 5% of assets and 10% of the issuer's voting securities per issuer.
Arithmetically entailed by '40 Act 5(b)(1) diversification (75%/5% asset leg) — it cannot fail independently, so it is reported outside the tally rather than counted as a separate check.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T063725 rates=20261113T063725
Measured on the 2026-11 formation date across 75 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 42.8% | 15.5% |
| 3 yearsp.a. | 40.1% | 8.5% |
| 5 yearsp.a. | 22.6% | 14.7% |
| 10 yearsp.a. | 16.0% | 7.2% |
| Since inceptionp.a. | 11.1% | 0.1% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 41.5% | 11.9% |
| 2025 | 51.0% | 8.7% |
| 2024 | 14.4% | 3.8% |
| 2023 | -7.1% | -12.2% |
| 2022 | 10.0% | 45.1% |
| 2021 | 8.3% | 33.2% |
| 2020 | 22.0% | -3.7% |
| 2019 | 19.9% | -11.1% |
| 2018 | -8.6% | 3.4% |
| 2017 | 26.8% | 9.8% |
| 2016 | -12.9% | 0.1% |
| 2015 | 13.6% | -3.8% |
| 2014 | 28.2% | 0.1% |
| 2013 | 45.7% | -9.4% |
| 2012 | 28.0% | 1.6% |
| 2011 | 6.4% | -1.9% |
| 2010 | 14.6% | 8.8% |
| 2009 | 19.2% | -6.8% |
| 2008 | -27.5% | -8.3% |
| 2007 | 2.3% | -6.7% |
| 2006 | 6.5% | 7.0% |
| 2005 | 4.2% | -8.4% |
| 2004 | -12.7% | -25.0% |
| 2003 | 30.5% | -8.3% |
| 2002 | -36.4% | -1.5% |
| 2001 | -10.4% | -0.5% |
| 2000 | 81.1% | -19.4% |
| 1999 | 24.1% | 23.2% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare ChEQ Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a ChEQ signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.